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Abstract 
 
In the wild, venom is crucial to many snakes’ success as predators. While antivenin 
research focuses on combatting venoms’ abilities to disrupt physiological processes, new 
studies are attempting to manipulate these same abilities into anticancer therapies. Given 
the diversity of neurotoxins, hemotoxins, cytotoxins, and others, every new discovery and 
development within snake venom research adds to the knowledge base and broadens 
applicational opportunities. Cancer-related venom research isolates various components, 
manipulates their interaction with target cancer cell lines, and evaluates how their natural 
biochemical activity counteracts mechanisms that are integral to tumor development. 
Several more promising components, namely disintegrins, lectins, oxidases, and 
phospholipases, have emerged. Summarizing and highlighting recent research of these 
key components can serve as a springboard for future venom-derived antitumor 
medicines. 
 Keywords: venom, cancer, apoptosis, integrin, angiogenesis, disintegrin, L-amino 
oxidase, lectin, phospholipase 
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Engineering the Rod of Asclepius – A Biochemical Investigation of Snake Venom 
Components and their Application as Potential Cancer Treatments 
  Differing from the Hermes’ caduceus in that it features a single serpent - rather 
than two - entwined about a staff, the Rod of Asclepius is an ancient symbol of medicine. 
Asclepius (Figure 1), born of Apollo and one of the four gods to whom the Hippocratic 
Oath is dedicated, is the patron Greek god of medicine and 
healing (Shetty, Shetty, & Dsouza, 2014). Though snakes and 
mankind have had complicated interactions since the Fall, the 
idea of the serpent around a staff has been symbolic of 
medicine for over 2400 years, dating back to the ancient 
Egyptians and Greeks and leading into the Renaissance period 
(Antoniou, Antoniou, Learney, Granderath, & Antoniou, 
2011). There are also biblical grounds for the symbol, 
stemming from Hebraic tradition and integrating into the 
Christian faith. At its earliest reference in the book of 
Numbers, the Israelites complained against God and were 
plagued by venomous snakes, but God showed grace by commanding Moses to make a 
bronze serpent and raise it up on a staff. Those who were bitten could look upon the 
bronze serpent and be healed (Numbers 21: 4-8, New International Version). The biblical 
foundation for snake-staff symbol is continued as Jesus declares, “Just as Moses lifted up 
the snake in the wilderness, so the Son of Man must be lifted up, that everyone who 
believes may have eternal life in him” (John 3:14-15). The symbol continues to represent 
Figure 1. Statue of Asclepius, 
God of Medicine, with his 
staff. From Asclepius, 
Britannica ImageQuest, 
https://quest.eb.com/search/as
clepius/1/300_169696/Asclep
ius/more. Copyright by 
Universal Images Group. 
Reprinted with permission. 
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medicine and healing today, such as in the logos of 
ambulances, hospitals, and the World Health Organization 
(Figure 2) (Shetty et al., 2014).  
The literal realization of the Rod of Asclepius (using snake venom to produce 
medicine) has been part of scientific history for centuries, and the idea flourishes today. 
The development of medicine from animal venoms and toxins began with folk medicine, 
but some of modern medicine’s recent toxin-derived drugs are antivenins. Due to the 
pressure of an increasingly health conscious world, drug developers have sought out 
natural resources for anticancer drugs. The biodiversity of animal venoms and toxins 
offers a wide range of structural templates for therapeutic agents, and certain venoms 
from snakes have active components that show anticancer activity (Gomes et al., 2010). 
Pertinent Biochemical Characteristics of Cancer 
Cancer is a chronic degenerative disease whose chief characteristic is 
uncontrolled cell proliferation, causing formation of tumors and possible metastasis 
(Calderon et al., 2014). Whether by personal suffering or that of a loved one or friend, 
cancer has affected most individuals around the globe. It is the second leading cause of 
death in modern countries, and GLOBOCAN (2013) reports indicate that 14.1 million 
new cases of cancer and 8.2 million cancer-related deaths occurred worldwide in 2012 
alone. Pancreatic, lung, breast, ovarian, and hepatic cancers are some of the most 
common types of cancer today (Torre et al., 2015). In today’s society, increasingly 
prominent risk factors such as obesity and pollution in both modern and third-world 
countries alike raise the worldwide morbidity rate each year (Global Cancer Observatory, 
2013). As progressing research scrambles to combat the mounting cancer cases and find a 
Figure 2. Official WHO 
logo (Global Cancer 
Observatory, 2013). 
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cure, comparative studies of normal and cancerous biology have revealed three cancer 
characteristics that can be specifically targeted by snake venom components: integrin 
malfunction, apoptosis inhibition, and angiogenesis. 
Integrins: Cell Growth, Progression, and Metastasis 
One of the most important aspects of cancer pathology is tumor cell development. 
A family of proteins called integrins are the key determinants in cell growth and 
progression. The molecular basis of tumor ontogenesis involves (dis)functional mutations 
of integrins, leading to adverse effects that trickle down into the processes they control: 
regulation of cell shape, cell survival rate, DNA transcription, and more (Figure 3) 
(Arruda Macedo, Fox, & de Souza Castro, 2015). 
Especially significant cancer-related processes 
coordinated by various types of integrins include 
cellular migration and invasion (Arruda Macedo et al., 
2015). Malignant tumors are also characterized by their 
anchorage-independent growth and metastasis 
formation (Eble & Haier, 2006). They require cell-to-
cell or cellular matrix attachment before they can proceed through the growth cycle (Eble 
& Haier, 2006). Integrins can mask  themselves as oncogenes and tumor suppressor 
genes before transforming biologically healthy cells into tumor cells (Eble & Haier, 
2006).  
Figure 3. Downstream cascade 
after integrin activation (Legate, 
Wickström, and Fässler, 2009). 
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According to Huveneers, Truong, and Danen (2007), some types of integrins are 
membrane receptors that mediate adhesion of cells to other cells and within the cellular 
matrix. Properly functioning integrins maintain an appropriate level of cell adhesion and 
migration as they respond to growth factors, cytokines, and other genetically modulated 
signals for cell progression 
(Figure 4) (Huveneers et al., 
2007). These regulatory 
functions of transmembrane 
integrins are the basis of 
their important roles in cell 
survival, proliferation, and differentiation (Huveneers et al., 2007). Comprised of natural 
integrin antagonists, many snake venom components such as disintegrins, peptides, and 
antibodies combat this aspect of cancerous growth (Huveneers et al., 2007).  
Apoptosis: Programmed Cell Death 
In normally functioning tissues, apoptosis is induced cell death that maintains 
cellular health and activity (Figure 5). After 
DNase is cleaved between its nucleosome 
links, apoptosis involves rapid phagocytosis 
and digestion of specified cells (Kerr, 
Winterford, & Harmon, 1994). It is 
suppressed at the genetic and ribosomal levels 
by RNases and protein synthesis inhibitors. 
Malignant tumors are characterized by their oncogenic ability to spontaneously cause 
Figure 4. Integrin-mediated cell adhesion (Lee, Choi, Cha, 
& Huang, 2015). 
Figure 5. Mechanism of apoptosis: p53 and 
caspase activity (Malhotra, Zaidi, Kosovec, & 
Kasi, 2013). 
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apoptosis in normal cells or in cells suffering from radiation or chemotherapy (Kerr et al., 
1994). Cancerous cells are also successful at suppressing their own apoptosis; cancer 
treatment can thus be rendered ineffective if a tumor induces and suppresses apoptosis 
effectively (Kerr et al., 1994).  
Implications of apoptosis suppression include the effective lengthening of a cell’s 
lifespan, allowing the cell to expand without dividing and aggregate with other similarly 
enlarged cells. At a genetic level, transcribed and synthesized growth factors and 
apoptosis-inducing checkpoint regulators can be destroyed or ignored when apoptosis is 
suppressed (Reed, 1999). If a malignant cell progresses and expands unchecked, it can 
accumulate genetic mutations that foster its ability to survive with less oxygen/nutrients, 
overcome natural immune responses, and resist anticancer drugs (Reed, 1999). Current 
cancer therapies focus on de-suppression and even upregulation of apoptosis in tumors, 
and cytotoxic components of snake venoms have mechanisms which are naturally 
efficient at this task. 
Angiogenesis and CPA: Neovascularization and Procoagulation 
In normal cells, new blood vessels are formed due to a process called 
angiogenesis. During their initial formation, tumors are able to survive by “sharing” the 
nutrients supplied by normal blood 
vessels. When their abnormally 
accelerated growth outpaces the 
regular supply of nutrients, they are 
able to create their own mini vascular 
system (Figure 6), creating an Figure 6. Tumor angiogenesis (Siemann, 2002). 
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intratumor network of constituent blood vessels (Ziyad & Iruela-Arispe, 2011). Research 
by Yeh, Peng, Tang, and Huang (2001) demonstrated that the mechanism of angiogenesis 
involves appropriately regulated reproduction, migration, and differentiation of 
endothelial cells in the cardiovascular system. Tumors combine highly interactive cell 
species, including fibroblasts and endothelial cells (Yeh et al., 2001). Such processes are 
controlled by angiogenic factors and extracellular integrins, but tumorigenic mutations of 
these proteins aid in unregulated angiogenesis, allowing tumor cells to develop their own 
blood vessels by which to siphon extra nutrients, growth factors, etc. (Yeh et al., 2001).  
In addition to creating their own vascular network, tumor cells possess 
procoagulant factors that cause thrombosis, a key complication that further decreases a 
cancer patient’s survival rate while ensuring tumor growth (Rickles & Falanga, 2001). 
Procoagulant mutations of cancerous oncogenes interfere with the normal processes of 
platelet interaction, fibrinolysis (prevention of clots), and regulation of vascular 
endothelium (Rickles & Falanga, 2001). Cancer procoagulant A (CPA) is a protease 
which deposits fibrin, a protein which impedes blood flow, and activating factor X, which 
has an important role in vascular thrombosis and initiation of coagulation (Gordon, 
Franks, & Lewis, 1975). Angiogenesis at an upregulated level allows nutrient-receptive 
tumors to survive, grow, and metastasize. Procoagulation of normal blood vessels 
simultaneously inhibits the survival of healthy tissues (Swenson, Ramu, & Markland, 
2007).   
Snake Venoms as Potential Cancer Therapies 
While research on many types of animal venoms has yielded successful 
anticancer results, snake venoms have an increased natural ability to cause large amounts 
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of tissue damage, and as such they show the most potential for imminent development 
into clinically-applicable cancer therapies. Researchers such as Calderon and his team 
(2014) have successfully demonstrated anti-expansion and anti-aggregation factors in 
snake venoms by using in vivo mouse tumors. Both crude venom and its isolated 
components have shown antitumor mechanisms that are promising for clinical trials 
(Calderon et al., 2014). In demonstrating their ability to disrupt cell adhesion and 
aggregation, induce apoptosis, prevent angiogenesis, and otherwise return cancer biology 
to a normal, healthy state, such enzymes as disintegrins, L-amino acid oxidases 
(LAAOs), lectins, and phospholipases A2 (PLA2s) have emerged as significant anticancer 
venom components (Calderon et al., 2014).  
Disintegrins 
Disintegrins are among the most wide-ranging and broadly applicable 
components of snake venoms. Walsh and Marcinkiewicz (2011) explained how snake 
disintegrins have been classified into three functional families: RGD (Arg-Gly-Asp), 
MLD (Met-Leu-Asp), and KTS (Lys-Thr-Ser). The letter motifs represent specific amino 
acid sequences in the structure of each disintegrins (Walsh & Marcinkiewicz, 2011). 
Because various amino acids exhibit differing molecular charges and properties, the 
unique peptide structure of each disintegrin makes it specifically fine-tuned to target its 
respective integrin-dependent processes (Walsh & Marcinkiewicz, 2011).  
Derivation and Isolation 
All venom disintegrins are found in five snake families: Viperidae, Crotalidae, 
Atractaspididae, Elapidae, and Colubridae (Arruda Macedo et al., 2015). RGD-
disintegrins are the most heavily researched and largest family, with derivations from all 
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five snake families (Walsh & Marcinkiewicz, 2011). Disintegrins that fall under the RGD 
category display the most variety in structure, function, and integrin targets; the Arg-Gly-
Asp hairpin sequence is the only 
predominating factor that unifies them 
(Walsh & Marcinkiewicz, 2011). MLD-
disintegrins are found exclusively in 
Viperidae, and their structures enable them 
to inhibit leukocyte integrins and improper 
adhesion of the cells they regulate (Walsh 
& Marcinkiewicz, 2011). They make up the 
most abundant disintegrin family, with the 
most investigated of MLD-disintegrins being from Vipera lebetina (Walsh & 
Marcinkiewicz, 2011). The first KTS-disintegrin was discovered by reverse phase 
chromatography of Vipera lebetina obtusa venom, and it was named obtustatin (Walsh & 
Marcinkiewicz, 2011). KTS-disintegrins are among the most selective, targeting a much 
smaller range of integrins with great specificity (Walsh & Marcinkiewicz, 2011). As 
proteins with low molecular weights, disintegrins are isolated by chromatography, as in 
Sánchez’ research (2006). It is their unique charge, molecular size, and other properties 
that determine which method of chromatography is most efficient: reverse phase, size 
exclusion, or anion exchange. Once the proteins have been purified, they are categorized 
according to mass spectrometry and experimental proteolytic activity (Sánchez et al., 
2006).  
 
Figure 7. Deciphering disintegrins: motifs 
within the hairpin turn (pink) and their 
corresponding targets (Munawar, Ali, Akrem, 
& Betzel, 2018). 
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Biochemical Activity as Tumor Antagonists 
The three disintegrin classes interact with their own sets of integrins. This specific 
pairing of inhibitor and target allows scientists to choose the disintegrin most suited to 
combat tumorigenicity in one specific area or cancer type. As an example of disintegrin-
integrin pairing, RGD-disintegrins block the activity of integrins α3β1, α4β1, α5β1, α6β1, 
α7β1, α8β1, αvβ1, αvβ3, αIIbβ3, and αvβ5 (Calderon et al., 2014). Contrary to their 
monomeric counterparts, MLD-motif disintegrins are heterodimeric, binding and 
inhibiting integrins α3β1, α4β1, α5β1, α6β1, α7β1, α9β1, αIIbβ3, and α4β7 (Calderon et 
al., 2014). As is expected of the most specific disintegrin class, only integrin α1β1 is 
affected by KTS-disintegrins (Calderon et al., 2014).  Despite their specific targets, all 
disintegrins use the same general mechanisms to combat tumorigenicity.  
One of the most central means by which disintegrins prevent cancer progression is 
by induced cell detachment. Disintegrins work in the extracellular matrix (ECM), and 
tumor cells that cannot adhere to the host cell 
network suffer severely limited nutrient supply and 
space for growth (Calderon et al., 2014). Because 
integrins also regulate cell checkpoint receptors and 
chemicals, such as cytokines, inhibition of their 
function renders the affected cell unviable. Unviable 
cancer cells are then phagocytized and disposed.  
Another mechanism by which disintegrins halt 
tumors is by downregulating proliferation of infected cells (Calderon et al., 2014). 
Without a means to grow and reproduce, the metastasis and progression of tumors is 
Figure 8. Disintegrin target: anti-
ADAM disintegrins would halt all 
processes regulated by ADAM, 
including proliferation, metastasis, 
etc. (Horiuchi et al., 2003). 
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stunted. Lastly, disintegrins especially high in disulfide bridges can be manipulated to 
target the growth factors of cancerous vascular endothelium, stopping angiogenesis and 
severing shunted vascular networks (Swenson et al., 2007). If disintegrins can 
simultaneously cut tumor cells off from their manufactured supply artery and prevent 
adhesion (and therefore nutrient uptake) to healthy cells, the cancer cells will have no 
means by which to grow, expand, invade, and migrate throughout the body. 
Current Experimental Trials 
Recent experiments and research have focused on various disintegrins’ abilities to 
successfully target and mitigate abnormal integrin function across several types of cancer. 
Scientists successfully observed and recorded one disintegrin, rhodostomin, as it inhibited 
basic fibroblast growth factor (bFGF), a signaling molecule necessary for angiogenesis in 
rodent melanoma (Yeh et al., 2001). Yeh’s research team (2001) injected mice with a 
subcutaneous tumor and then treated them with rhodostomin. The disintegrin successfully 
prolonged survival by inhibiting neovascularization (angiogenesis) and by blocking 
tumor cell migration and invasion of normal cells (Yeh et al., 2001). Research by Lucena 
et al. (2015) demonstrated that the disintegrins mojastin and viridistatin efficiently 
inhibited tumor metastasis in human pancreatic carcinoma; rates of successful inhibition 
increased with correlating dose increases (2015). The two recombinant disintegrins also 
downregulated carcinoma proliferation while inducing its apoptosis, a result of 
significance because pancreatic cancer is often immune to chemotherapy methods 
(Lucena et al., 2015).  
A disintegrin called contortrostatin (CN) has been through numerous trials and 
has successfully prevented tumorigenicity of many different types of cancer, attracting 
TREATING CANCER THROUGH SNAKE VENOMS 14 
notable interest in initial disintegrin cancer research (Golubkov, Hawes, & Markland, 
2003). Derived from Agkistrodon contortrix (a southern copperhead), CN has 
successfully inhibited migration and invasion of cancerous human umbilical vein cells 
(HUVEC) in research by Golubkov (2003) and others. Contortrostatin disrupted cancer 
progression in HUVEC by four mechanisms: blockading integrin-dependent cytoskeleton 
actin filaments (internal cell structures), altering intercellular cadherin (allows cells to 
attach to one another), downregulating focal adhesion kinase (manufactures adherins), 
and inhibiting tyrosine phosphorylation (an important signal transduction regulator) 
(Golubkov et al., 2003). Beyond its success against malignant HUVEC, CN also inhibited 
angiogenesis in cancer-inoculated mice (Golubkov, Hawes, & Markland, 2003). 
Markland and his associates performed experiments in 2001 which observed CN 
hindering human ovarian adenocarcinoma. By blocking adhesion to extracellular proteins 
and creating a fake basement membrane through which invasive cells could not penetrate, 
CN prevented aggregation and migration of an ovarian cancer tumor in vitro (Markland 
et al., 2001). Studies with melanoma (skin cancer) indicate that CN uses similar 
mechanisms to prevent its metastasis: melanoma cells are blocked from adhering to 
extracellular proteins, more specifically collagen, fibronectin, and vitronectin (Trikha, De 
Clerck, & Markland, 1994). It is important to note that inhibitory effects are enhanced 
with increased experimental doses of CN, without harm to surrounding normal cells 
(Trikha et al., 1994).  
In an experiment involving the inoculation of mice with metastatic human 
mammary cancer, Swenson et al. found that unlike ovarian, skin, and HUVEC cancers, 
breast cancer did not respond well to clinical trials of intratumor CN injections (2004). 
TREATING CANCER THROUGH SNAKE VENOMS 15 
While intratumor injections of CN were met with adverse effects, the researchers 
observed that a liposome-CN recombinant administered intravenously induced 
antiangiogenic activity successfully (2004). Researchers suggest that because of these 
results, LCN could serve as the more advantageous alternative to intratumor CN in all 
cases for the following reasons: LCN circulates more effectively and conservatively 
through the bloodstream, LCN is passively taken up into the tumor (rather than forced 
injection), LCN causes no platelet immune response, and LCN is not tagged as a foreign 
substance by the immune system in other parts of the body (Swenson et al., 2004). 
Relevant Drugs on the Market 
Clinical drugs have yet to be produced from pure isolations of snake venom 
disintegrins, but researchers have developed several peptidomimetics which mimic the 
structure and function of disintegrins, two of which are readily available in clinical 
sectors. Tirofiban (marketed by Aggrastat) mirrors the Arg and Asp interaction of RGD-
disintegrins, allowing it to bind to αIIbβ3 and αvβ3 (Arruda Macedo et al., 2015). 
Tirofiban combats the procoagulant activity of GPIIb-IIIa, instead promoting platelet 
adhesion and vascular cell health (Arruda Macedo et al., 2015). As an FDA-approved 
anticoagulant, it is currently used as a clinical treatment of myocardial infarction (heart 
attack) and refractory ischemia (chest pain due to inadequate blood supply to the cardiac 
muscles) (Arruda Macedo et al., 2015). Eptifibatide markets Integrilin, which was 
founded upon screenings of sixty-two different snake venoms (Arruda Macedo et al., 
2015). Barbourin is the main foundation for Integrilin, which mimics the function of the 
KGD-disintegrin of Sistrurus miliarus barbouri and binds exclusively to αIIb3 integrin 
(Arruda Macedo et al., 2015). Integrilin is FDA-approved for treatment of acute coronary 
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syndromes (Arruda Macedo et al., 2015). Though current disintegrin-based drugs on the 
market are not clinically used as cancer therapies, each successful trial and manipulation 
of the biochemistry of disintegrin is one step closer to its clinical use to combat 
tumorigenicity. 
Future Research: Opportunities and Limitations  
Future research of disintegrins as potential cancer therapies is met with both 
opportunities and road blocks. Cancer operates by complex mechanisms that are 
consistently changing with environmental factors, biological mutations, and population 
dynamics. This every-changing complexity therefore presents the challenge of 
discovering and isolating the exact function for any given integrin and its disintegrin 
counterpart. While this is a daunting task, the same complexity allows for specificity in 
attacks on cancer. Unlike chemotherapy or radiation, which produce widespread damage 
to cancerous and healthy cells alike, development of therapies based in integrin-
disintegrin pairs will target tumor cells with fewer adverse effects to healthy cells 
(Arruda Macedo et al., 2015). 
Another problem that hinders the progress of disintegrin-based cancer treatments 
is the limited supply of natural resources and the instability and immunogenicity of 
chemically engineered mimics (Kim et al., 2003). As with any natural resource, snake 
venom is in limited supply, and ethics of animal care make harvesting snake venom and 
experimental trails increasingly difficult. On the other hand, synthetic inventions that 
mirror the structures and functions of natural disintegrins are still unstable and can 
provoke immune responses in healthy cells (allergies) (Kim et al., 2003). This is the case 
with many peptide drugs, but scientists such as Kim et al. are experimenting with the 
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fusion of disintegrin-coding genes into cationic liposomes (2003). This process 
circumvents immune responses due to a peptide foundation, and the resulting genetically-
modified liposomes can introduce and express disintegrin genes once they are injected 
into a tumor (Kim et al., 2003). 
As a last resort, researchers are isolating and manipulating antibodies that have 
very similar functions to disintegrins, but trials thus far have proven that disintegrins are 
a better alternative to antibodies (Leong-Poi, Christiansen, Klibanov, Kaul, & Lindner, 
2003). Disintegrins decay at faster rates, a desirable characteristic in that after injection 
and action, disintegrins will not remain in the body indefinitely (with unknown effects) 
(Leong-Poi et al., 2003). A second advantage of disintegrins is their controllability. At 
any point in time, after the disintegrin has been injected and has inhibited its target, it can 
be inhibited itself in case upregulation of integrins is abruptly necessary (Leong-Poi et 
al., 2003). Lastly, disintegrins are both cheaper and are more readily available than 
antibodies (Leong-Poi et al., 2003). 
L-Amino Acid Oxidases 
Dimeric flavoenzymes called L-amino acid oxidases exist within many diverse 
biological kingdoms such as fungi, bacteria, algae, and snakes (Calderon et al., 2014). 
From a biochemical standpoint, LAAOs form alpha-keto acids, hydrogen peroxide, and 
ammonia by deaminating L-amino acids in aerobic conditions (Calderon et al., 2014). 
Because these chemical byproducts can be harmful depending on where they are 
deposited, LAAOs are often classified by their location-dependent function (Calderon et 
al., 2014). Some categories of LAAOs are organized by their substrate preference (must 
TREATING CANCER THROUGH SNAKE VENOMS 18 
be aerobic), cytotoxicity, induction of apoptosis, platelet effects, or bactericidal 
mechanisms (Calderon et al., 2014).  
 
 
Derivation and Isolation 
Snake venom L-amino acid oxidases (svLAAOs) can be isolated from all snake 
families, but Viperidae, Crotalidae, and Elapidae venoms are richest in LAAOs, which 
interestingly give venoms their characteristic yellow color (Guo, Liu, Yao, Zhang, & 
Sun, 2012). As in research by Toyama’s team (2006), most svLAAOs are isolated by 
molecular exclusion and ion exchange chromatography. Purification and identification 
are accomplished by reverse phase chromatography, gel electrophoresis, and 
spectrophotometric analysis of amydolitic activity (ability to cleave amide groups) 
(Toyama et al., 2006).   
Biochemical Activity as Tumor Antagonists 
In their natural application, LAAOs are extremely cytotoxic, first and foremost 
causing necrosis (Calderon et al., 2014). There are a few mechanisms by which varying 
svLAAOs induce apoptosis. At initial exposure, LAAOs cause hypotension (low blood 
pressure) and upregulate the production of hydrogen peroxide in the cell (Calderon et al., 
2014). Hydrogen peroxide breaks down cell walls and membranes, causing cell lysis and 
death. svLAAOs that are manipulated and paired with targeting nanoparticles can 
therefore be injected into tumor cells to lyse their membranes, with negligible damage to 
Figure 9. Biochemical reaction of LAOO to alpha-keto acid, hydrogen 
peroxide, and ammonia (Worthington Biochemical Corporation, 2019). 
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surrounding normal cells (Calderon et al., 2014). In addition to the production of excess 
hydrogen peroxide, LAAOs can interfere with intra- and intercellular membrane 
receptors, stunting cell communication (Costa, Burin, Menaldo, de Castro, & Sampaio, 
2014). This communication breach can cause an immune response to tag the affected cell 
as foreign and malfunctional, inducing apoptosis (Costa et al., 2014). Induction of 
apoptosis can also stem from premature activation of caspases 3 and 9, which are parts of 
the mitochondrial pathway of anti-apoptotic and death receptors. As oxidases, these 
flavoenzymes produce reactive oxygen species that activate caspases (Guo et al., 2012). 
Once the caspases are activated, cytochrome c is released, apoptosis-inducing ligands are 
synthesized, and vital proteins are cleaved, leading to cell death (Guo et al., 2012).  
Though their main function is to upregulate cellular apoptosis, LAAOs also have 
platelet aggregation and cell cycle arrest capabilities. Experimental results have been 
lacking in consistency and agreement, and svLAAOs have been observed to both induce 
platelet aggregation and inhibit it, depending on LAAO isoforms, cellular location, and 
types of platelets involved (mouse vs human, washed vs platelet rich plasma) (Sakurai et 
al., 2001). Induction of aggregation can theoretically be used to target tumors’ 
neovascular systems to stop the flow of nutrients and oxygen to cancerous cells. On the 
other hand, aggregation-inhibiting isoforms can be injected into cells suffering from 
cancer-related procoagulant effects, therefore reducing thrombosis-related cancer 
complications (Sakurai et al., 2001). Concerning the arrest of cell growth, it has been 
observed that svLAAOs interfere with thymidine uptake into the cell (Ahn, Lee, & Kim, 
1997). Thymidine is an important component in DNA and interrupting its incorporation 
into the cell genome can halt cell progression through the S phase of growth, 
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discontinuing progress to cell growth and proliferation (Ahn et al., 1997). This prevents 
tumor proliferation and expansion.  
Current Experimental Trials 
As with disintegrins, different svLAAO variants produce antitumor results 
consistent with their isoforms, molecular weights, peptide structures, and other defining 
properties (Mukherjee, Saviola, Burns, & Mackessy, 2015). In research by Mukherjee et 
al., one LAOO called rusvinoxidase (harvested from the venom of Daboia russelli 
russelli) successfully induced apoptosis in breast cancer cells by corrupting cell 
morphology, activating DNases, destabilizing membrane proteins, and initiating cell 
shrinkage (2015). Even after freezing and thawing, rusvinoxidase activated caspase-8 and 
the release of cytochrome c to activate caspase-9, while simultaneously downregulating 
anti-apoptotic proteins Bcl-XL (Mukherjee et al., 2015). Activity of rusvinoxidase is both 
time and dose-dependent, but trials indicate that up to 4 mg/kg is non-toxic to normal 
mouse cells, encouraging prospective tests on cancer-affected human cells (Mukherjee et 
al., 2015).  
Venom extraction from another snake, Agkistrodon acutus, yielded another 
svLAAO: ACTX-8 (Zhang & Wei, 2007). ACTX-8 induced apoptosis of Hela cervical 
cancer cells by DNA fragmentation and caspase induction (Zhang & Wei, 2007). 
According to Zhang and Wei, one unique aspect of ACTX-8 is its ability to cause anti-
apoptotic proteins to move from the cellular matrix to the mitochondria, where they are 
bound to dissociating enzymes and broken down (2007). The production of reactive 
oxygen species interferes with antioxidant-sensitive mechanisms in the mitochondria, 
further fostering cell failure and death (Zhang & Wei, 2007). The specific method of 
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enzyme translocation is still unknown, but further research may introduce anti-apoptotic 
inhibition as a new mechanism of cancer therapy where traditional mechanisms are 
unsuccessful.  
A third cancer proven to suffer apoptosis induction in the presence of svLAAOs is 
prostate cancer. In research by Tan et al., Crotalus mitchellii pyrrhus venom was 
extracted, and Cmp-LAAO was isolated by chromatography (2017). Prostate cancer cells 
(LNCaP) suffered premature apoptosis and oxidative stress after injection of appropriate 
concentrations of Cmp-LAAO (Tan, Ler, Gunaratne, Bay, & Ponnampalam, 2017). Cmp-
LAAO targeted activation of caspase-3 and 9, while production of hydrogen peroxide 
was a secondary yet harmful effect (Tan et al., 2017). Cmp-LAAO showed preferential 
specificity for cancer cells but did produce cytotoxic effects in normal cells at certain 
concentrations, so more research and trials must be developed before it is an adequate 
and safe prostate cancer therapy (Tan et al., 2017). 
Future Research: Opportunities and Limitations  
Though no drugs based on svLAAOs have been developed, their anti-tumor 
effects and abilities have not gone unnoticed. As studies within the past decade have 
yielded successful evidence of svLAAOs in combatting cancer, related research has 
earned respect and increased attention. Caspase activation, thymine blockage, membrane 
receptor instability, and cell membrane breakdown are some mechanisms of apoptosis 
induction which are unique to svLAAOs. Recent progresses have revealed that svLAAOs 
act preferentially against cancer cells before attacking mammalian cells in the same 
region (Guo et al., 2012). This should encourage research that helps streamline the 
targeting process, in order to eliminate any negative effects svLAAOs might induce in 
TREATING CANCER THROUGH SNAKE VENOMS 22 
healthy cells. At the same time, such efficient mechanisms that show marked preference 
for cancer cells over normal cells may cement the role of svLAAOs as foundational for 
synthetic anti-tumor mimic drugs and therapies. One disadvantage of svLAAOs is their 
high molecular masses, which makes them stand out as unusually large or dense 
glycoproteins and creates issues with immunogenicity and allergic reactions to derivative 
cancer treatments (Guo et al., 2012). 
Lectins 
Lectins are (glyco)protein subunits with carbohydrate binding sites. Though they 
can be found in several animal and vegetable species, snake lectins (snaclecs) have been 
proven to inhibit tumorigenicity in a few different cancer types (Calderon et al., 2014). 
Their key importance to cancer research involves their interaction with a tumor cell’s 
surface (Calderon et al., 2014). Lectins are unique 
venom-derived cancer antagonists because their 
dimeric tertiary units can bind together and 
aggregate into quaternary structures stabilized by 
disulfide bonds (Doley & Kini, 2009). Lectins 
bind by two mechanisms, the first being a lock-
and-key model where their subunits fit exactly 
with specific carbohydrates (Lu, Navdaev, Clemetson, & Clemetson, 2005). This 
specificity allows for the manipulation of lectins for tumor cell identification based on the 
carbohydrates, proteins, and other molecules on cell surfaces (Lu et al., 2005). 
Carbohydrates located on the cell membrane are especially important in cell-to-cell 
interactions.  Thus, lectin-carb interactions heavily influence how abnormal cells are 
Figure 10. Lectin folding structure 
provides three specific binding sites: α, β, 
and γ (Kapoor, Vaidya, Kaur, & Jain, 
2014). 
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tagged and their extracellular binding is regulated (Lu et al., 2005). Lectins also bind via 
electrostatic interactions in which the charges and properties of amino acids in their 
primary peptide structures determine binding or repulsion (Lu et al., 2005). With slight 
genetic mutations or synthetic manipulation, lectins can undergo structural changes 
which allow multiple binding sites or selectivity for a greater range of cell 
proteins/receptors (Lu et al., 2005).  
Derivation and Isolation 
Snaclecs typically fall under two classes: C-type lectins (CTLs) and C-type lectin 
related proteins (CLRPs). They are found in all snake families, and they comprise a 
majority of venoms within the Viperidae and Colubridae families (Doley & Kini, 2009). 
As with other components of snake venom, 
lectins are purified from crude venom by 
chromatography, specifically affinity and get 
filtration chromatography (Nunes et al., 2011). 
Fluorescence emission spectra are used to 
determine the tryptophan peptide residues present 
in the various lectins, while circular dichromism 
reveals their secondary structures (α-helix or β-
sheet) (Nunes et al., 2011).   
 
 
 
 
Figure 11. Lectin shape determines 
lock-and-key fit (Kapoor et al., 2014). 
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Biochemical Activity as Tumor Antagonists 
Lectins exhibit antitumor activity in a few ways. Like disintegrins, some lectins 
from specific snake families block the progression of integrin-dependent growth 
processes, but lectin also works uniquely against the actin dis(assembly) and therefore 
halts cell proliferation (Calderon et al., 2014). Other lectins prevent adhesion within the 
extracellular matrix, fighting tumor cells for intercellular binding sites and immobilizing 
weakly adhered cancer cell lines (Calderon et al., 2014). Activity specific to C-type 
lectins includes induction of red blood cell agglutination and platelet aggregation (Doley 
& Kini, 2009). CLRPs differ from CLTS in that they cannot bind to carbohydrates, but 
instead have only hemostatic mechanisms 
(Doley & Kini, 2009). As do disintegrins and 
LAAOs, CLRPs vary in their structure and 
their consequential functions, varying from 
platelet aggregation/activation to anti- or 
procoagulant factor binding (Doley & Kini, 2009). Many CLRPs disturb the coagulation 
process by targeting and inactivating thrombin, diminishing clot-related cancer 
complications (Doley & Kini, 2009). 
Current Experimental Trials 
Lectins reduce cancer patients’ cardiovascular complications by their variety of 
coagulant activity, whether excitatory or inhibitory, but their hindrance of cell 
proliferation is also important in cancerous cells themselves. Experimental trials with 
BJcuL from Bothrops jararacussu have supported this lectin’s inhibitory effect on human 
renal and pancreatic cancer cell lines (de Carvalho, Schmitmeier, Novello, & Markland, 
Figure 12. Different lectins, based on genetic 
function and carbohydrate specificity, can induce 
or inhibit coagulators (Santos et al., 2013).  
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2001). BJcuL also binds to intercellular receptors on the membranes of human ovarian 
and breast cancer cells, effectively detaching the cell from the extracellular matrix as 
BJcuL concentration was raised (Doley & Kini, 2009). Detaching cancer cells cuts off 
pathways of communication and nutrient uptake, inhibiting growth of tumor cells and 
endothelial cells (needed for angiogenesis) (Doley & Kini, 2009). Other studies and 
manipulations of BJcuL have yielded positive agglutination results: the lectin binds to 
lactose moieties and causes erythrocytes to agglutinate (de Carvalho et al., 2001). By 
decreasing cell adhesion and proliferation and increasing agglutination, BJcuL decreases 
the viability of tumor cells in tested human and bovine cancer lines.  
Botrocetin and bitiscetin are two well-studied CTLs which bind to GPIb receptors 
on platelets and cause agglutination. By recreating crystallography pictures of the two 
lectins, Lu et al. and other research teams have determined that specific binding of lectin 
subunits to their matching GPIb domains enhances lectin-receptor binding efficiency, 
which is significantly more advantageous than forcing conformational changes as do 
some enzyme-substrate complexes (2005). 
Komori et al. studied a unique lectin called A lectin, from Agkistrodon piscivorus 
piscivorus (the water moccasin), which belongs to the C-type lectin related protein family 
(1999). The disulfide-linked monomers allow this lectin to agglutinate erythrocytes in 
human ad rabbit cancer cells (Komori, Nikai, Tohkai, & Sugihara, 1999).  
Future Research: Opportunities and Limitations  
Present studies have established the role of snaclecs in preventing tumor cell 
proliferation and varying platelet aggregation. While these roles and effects have been 
observed and replicated, the mechanisms by which lectins accomplish their functions 
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remain unknown. Lectins are one of the lesser-studied snake venom components, so more 
studies are needed before research can confirm their apoptotic, anti-angiogenic, anti-
proliferation, and cardiovascular effects in different cancer types and different 
environmental conditions (de Carvalho et al., 2001). 
Carbohydrate recognition is the basis for the targeting efficiency seen in lectin-
based trials. As mentioned earlier, structural changes of lectins can affect how they 
interact with receptors, integrins, and other cell features important to cancer biology. 
Studies today focus on establishing correct models of lectin varieties and understanding 
the carbohydrate-lectin pairing mechanisms (Nunes et al., 2012). Once these aspects are 
better understood, cancer therapies which use lectins can streamline the efficiency of the 
lectins’ electrochemical/shape-fit mechanism. Paired with targeting agents with even 
higher specificity, lectins in all their variety can be used for specific cancer types without 
risk of harm to healthy cells (Nunes et al., 2012). The ever-changing dynamics of 
oncology and genetic mutations of various cancer types increase therapy 
immunogenicity, or the ability of cancer cells to tag drugs as foreign entities for 
destruction (Nunes et al., 2012). Gene distribution among cancer cells helps them evoke 
immune responses to treatments such as chemotherapy; these immune responses attack 
and eliminate the medicines before they can destroy the cancer (Nunes et al., 2012). New 
drugs based on natural components such as snaclecs can reveal more effective, resilient, 
and longer-lasting cancer treatments. 
Phospholipases A2 
Phospholipases A2 are clinically important today for their role in inflammatory 
diseases and lipid catabolism. They are characterized based on their amino acid 
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sequences and other biochemical characteristics. Snake venom phospholipases A2 
(svPLA2) are divided into three families: acidic, basic, and peptide homologues 
(Calderon et al., 2014).  
Classification and Derivation 
svPLA2s are present in all snake venoms, but those derived from the Viperidae 
family are most commonly used for cancer research; their mechanisms are therefore the 
most understood and applicable to future cancer therapies (Higuchi et al., 2007). Gel 
filtration, ion exchange, and reverse phase chromatography are used in the purification of 
these phospholipases (Higuchi et al., 2007). Once isolated, the PLA2 activity is best 
measured by a spectrofluorometer, which measures and records substrate fluorescence at 
a specific wavelength (Higuchi et al., 2007).   
Biochemical Activity as Tumor Antagonists 
While apoptosis, integrins, and angiogenesis are focal components of cancer, 
another minor mechanism by which cancer invades and migrates through the body is by 
altered lipid synthesis and downregulated 
lipogenesis. svPLA2s can mitigate these 
lipid synthesis changes by altering cell 
membrane metabolism (Calderon et al, 
2014). Such alterations affect microtubules 
ad focal adhesions between cells, as with the 
PLA2 of Macrovipera lebetina 
transmediterranea (Calderon et al., 2014).  
Figure 13. Binding of snake PLA2 to lipid 
membrane (Alekseeva et al. 2017). 
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 PLA2s destabilize the lipid bilayer of the cell membrane. In the presence of 
calcium, phospholipid bonds are hydrolyzed to produce free fatty acids, molecules which 
cannot be incorporated into the lipid bilayer until they are rebonded (Vyas, Brahmbhatt, 
Bhatt, & Parmar, 2013). Such hydrolysis of the lipid bilayer weakens the integrity of the 
cell membrane, allowing for the release of bioactive products, cell shrinkage, and 
problems of cell adhesion (Vyas et al., 2013).  
By the primary means of lipid 
destabilization and membrane disruption, 
PLA2s employ mechanisms that combat the 
three focal components of cancer. They have 
been observed to reduce cancer cell viability by 
50%, as cells without intact membranes cannot 
survive (Higuchi et al., 2007). Another type of 
svPLA2, though it did not interfere with platelet aggregation, did inhibit plasma clotting 
(Higuchi et al., 2007). Plasma cells injected with PLA2 suffered membrane breakdown, 
resulting in communication loss and tagging for apoptosis (Higuchi et al., 2007).   
Current Experimental Trials 
Studies observing svPLA2 interactions with cancer cells in vivo and in vitro are 
few and far between, as most PLA2 focus has been on anti-inflammatory uses. However, 
two emerging svPLA2s are VRCTC-310 and Lys49 PLA2. VRCTC-310 is a purified 
PLA2 from the venom of Naja haje (Costa et al., 1997). In their research (1997), 
VRCTC-310 significantly inhibited metastasis and induced apoptosis in patients after a 
30-day treatment. Researchers found, however, that with this treatment of mice and 
Figure 14. PLA2s attach, weaken, and 
lesion lipid bonds in the cell membrane 
(Mora-Obando, Fernández, Montecucco, 
Gutiérrez, and Lomonte, 2014).  
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human cancer in vivo, side effects such as eosinophilia (abnormal white blood cell count) 
and palpebral ptosis (paralysis of the eye muscles) were experienced (Costa et al., 1997). 
Further studies will consider finding the components producing adverse reactions and 
isolating the lipid-lysing components of VRCTC-310 to create synthetic mimics. 
In another study by Araya and Lomonte, Lys49 PLA2 was injected 
subcutaneously into five murine cancer cell lines: melanoma, mammary carcinoma, 
sarcoma, myeloma, and cancerous endothelial cells (2007). All five cancer cell lines 
showed marked lipid lysis by the peptides (Araya & Lomonte, 2007). Tumor growth was 
significantly stunted, and tumor recession proceeded until tumors were about 64% of 
their original size (Araya & Lomonte, 2007). Scientists especially praised these results 
because they were achieved by similar methods and doses as paclitaxel, an anticancer 
drug currently in clinical use (Araya & Lomonte, 2007). This similarity in results but 
with a novel source encourages research of svPLA2s as potential natural cancer therapies. 
Future Research: Opportunities and Limitations 
Research on PLA2s from snake venoms is still in its earlier stages. Unlike with 
disintegrins, LAOOs, and lectins, PLA2s are difficult to extract. While successfully 
isolated samples have demonstrated the promising nature of PLA2s to destabilize the 
lipid membranes of cancer cells, scientists are still struggling to pair snake PLA2s with 
agents that help them differentiate between normal and cancerous cells. Disintegrins, 
LAOOs, and lectins remain at the forefront of venom-based cancer treatment 
developments and experiments, but any discovery and breakthrough with PLA2s 
introduces for yet another mechanism by which cancer can be treated when other 
methods fail.   
TREATING CANCER THROUGH SNAKE VENOMS 30 
Conclusion 
Because cancer is one of the most common and feared diseases, it is imperative 
that scientific research develops cancer treatments quickly and effectively. Chemotherapy 
and radiation are the two traditional treatments, and they focus on the undifferentiating 
killing of cancerous tissues, even if normal cells are affected too. Research on snake 
venoms and their components has produced some promising results as experiments have 
put disintegrins, L-amino acid oxidases, lectins, and phospholipases to the test. Recent 
research continues to reveal fascinating and practical details about cytotoxicity and the 
mechanisms of inhibiting tumorigenicity.  
Rather than attacking all regionally-affected cells, specific aspects of cancer 
progression are now becoming targets, including increased growth and proliferation, 
avoidance of apoptosis, and angiogenesis. These overarching characteristics of cancer 
cells lead to invasion, metastasis, and interruption of normal cell function, but 
components of snake venom have been found to directly hinder such activity. Now the 
invention of new treatments is expanding to include factors that reduce cell adhesion, halt 
neovascularization, destabilize cell membranes, and activate caspase-mediated apoptosis.  
This thesis discussed four significant components of snake venom: disintegrins, 
L-amino acid oxidases, lectins, and phospholipases. General isolation and derivation of 
these components was described, and their biological effects on cancer cells were 
explained. Lastly, current research of each target-specific component and its effects was 
summarized to provide background for the leading opportunities and problems with 
future experimental directions.   
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Finding weaknesses in the mechanisms of tumor progression starts with isolating 
the compounds that inhibit these focal processes, and scientists have found potential 
solutions in snake venom components. Further trials may pair the natural abilities of these 
components with synthetic manipulation to inhibit angiogenesis, induce apoptosis, inhibit 
proliferation, etc. Such trials and their success are essential to the search for new drugs 
and cancer inhibitors that combat the wide variety of cancer mechanisms. With the 
development of cancer treatments using snake venom components, one of many 
manifestations of the Rod of Asclepius will be realized. 
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